CLINICAL TRIAL / NCT05554328 - UChicago Medicine

A Randomized Trial of Selumetinib and Olaparib or Selumetinib Alone in Patients With Recurrent or Persistent RAS Pathway Mutant Ovarian and Endometrial Cancers: A ComboMATCH Treatment TrialThis phase II ComboMATCH treatment trial compares selumetinib plus olaparib toselumetinib alone in women with endometrial or ovarian (fallopian tube and primaryperitoneal) cancer that has come back (recurrent) or that remains despite treatment(persistent) and harbors a mutation in the RAS pathway. Selumetinib may stop the growthof tumor cells by blocking some of the enzymes needed for cell growth. Olaparib is aninhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when itbecomes damaged. Blocking PARP may help keep tumor cells from repairing their damagedDNA, causing them to die. PARP inhibitors are a type of targeted therapy. The addition ofolaparib to selumetinib could increase the percentage of tumors that shrink as well aslengthen the time that the tumors remain stable (witho...